On August 29, 2023 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, reported that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-15, 2023 (Press release, Chemomab, AUG 29, 2023, View Source [SID1234634741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors may view the Chemomab presentation online beginning on September 11, 2023, at 7:00 AM ET via the following link: View Source

This link will remain active for 90 days. It will also be available at the investor section of the Chemomab website at View Source

Chemomab senior management will be available for virtual one-on-one meetings with investors during the conference from September 11 through September 14, 2023. For information about the conference and to register to meet with Chemomab management, visit View Source